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Abstract
We report on peptide-based ligands matured through the protein catalyzed capture
(PCC) agent method to tailor molecular binders for in vitro sensing/diagnostics and
in vivo pharmacokinetics parameters. A vascular endothelial growth factor (VEGF)
binding peptide and a peptide against the protective antigen (PA) protein of Bacillus
anthracis discovered through phage and bacterial display panning technologies,
respectively, were modiﬁed with click handles and subjected to iterative in situ click
chemistry screens using synthetic peptide libraries. Each azide-alkyne cycloaddition
iteration, promoted by the respective target proteins, yielded improvements in metrics
for the application of interest. The anti-VEGF PCC was explored as a stable in vivo
imaging probe. It exhibited excellent stability against proteases and a mean elimina-
tion in vivo half-life (T1/2) of 36 min. Intraperitoneal injection of the reagent results in
slow clearance from the peritoneal cavity and kidney retention at extended times,
while intravenous injection translates to rapid renal clearance. The ligand competed
with the commercial antibody for binding to VEGF in vivo. The anti-PA ligand was
developed for detection assays that perform in demanding physical environments.
The matured anti-PA PCC exhibited no solution aggregation, no fragmentation when
heated to 1008C, and > 81% binding activity for PA after heating at 908C for 1 h.
We discuss the potential of the PCC agent screening process for the discovery and
enrichment of next generation antibody alternatives.
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1 | INTRODUCTION
Monoclonal antibodies (mAbs) are the current standard as bio-
logical recognition elements for in vitro and in vivo applica-
tions. While the reputation of mAbs for high aﬃnity and
selectivity is often overstated,[1] they do consistently perform
better than most reported alternative capture agent technolo-
gies. However, thermal and biological instabilities, batch-to-
batch variability, and molecular size can limit the eﬀectiveness
of mAbs. For example, antibodies often lack the stability to
serve as capture agents for environmentally demanding appli-
cations.[2] As a second example, the large size of mAbs can
yield attractive pharmacokinetic (PK) properties for certain
therapeutic tasks. However, their large size can also prevent
the rapid in vivo clearance often required for in vivo imaging
tasks.[3,4] Some of these drawbacks are being actively
addressed,[5] including the work by McConnell et al. to pro-
duce stabilized IgG frameworks that can maintain >60% bind-
ing activity after 1 h at 908C.[6]
Various oligonucleotides,[7] small biologics,[8–11] or pep-
tide capture agents that are developed through screening
methods may be engineered for such demanding tasks. For
example, several small biologics have been shown to exhibit
high melting onsets in buﬀered solution. These include
Adhirons (1018C),[12] Aﬃbodies (>908C),[13] and DARPins
(up to 968C),[11] although the binding activity following such
thermal treatments has not been reported. The common deﬁ-
nition of thermal stability (Tm), as applied to these alternate
scaﬀolds, does not capture the full range of relevant proper-
ties, since a high melting point reagent can lose signiﬁcant
binding activity after prolonged exposure to high heat. A rel-
evant example is a single domain antibody-maltose fusion
protein.[14] Small mAb biologics can exhibit improved tissue
and solid tumor penetration relative to mAbs, but can also
exhibit short serum half-lives due to enzymatic degradation
and rapid renal clearance.[15]
Peptide-based ligands are straightforward enough to
develop using cellular display methods,[16,17] but typically
exhibit target selectivity and aﬃnity properties that are infe-
rior to mAbs. However, such peptide structures are—like
small molecules—not susceptible to misfolding, and are
amenable to strategic molecular alterations. Methods for
improving the performance of such artiﬁcial antibodies have
advanced in recent years. Herein we explore protein cata-
lyzed capture (PCC) agent technology[18] as a method for
iteratively improving the properties of peptide ligands origi-
nally discovered through alternative approaches.[19]
For the PCC method used here, the original ligand is
chemically modiﬁed to present an azide (or alkyne) click
handle and a biotin assay handle. This modiﬁed ligand is
called the anchor. The anchor is then incubated with a large
one-bead-one-compound (OBOC) peptide library designed
to present the complementary alkyne (or azide) click handle.
The azide-alkyne cycloaddition reaction is commonly pro-
moted by a Cu(I) catalyst.[20,21] For an in situ click screen,
no Cu(I) catalyst is used. Instead, the protein target, itself,
provides an exquisitely selective scaﬀold by promoting the
click reaction between the target-bound anchor and those
few library elements that will bind to the target in just the
right geometry relative to the anchor.[18a] Unlike most
screening methods, the PCC approach does not screen for
the binding of library elements to the target. Instead, the
screen is designed to identify the in situ click reaction prod-
uct, which are those beads that contain covalently coupled
anchor. The PCC process can be used to develop linear,
branched, and/or cyclic peptide architectures.
In the present study, we explore the tunability of 2 diﬀer-
ent PCCs for speciﬁc in vitro and in vivo applications. Each
PCC anchor was developed from a peptide ligand identiﬁed
using bacterial or phage display screening, and subsequently
tailored for the targeted application through the use of in situ
click screens. We describe the development, as well as the
resulting in vivo performance and biological stability metrics
of an anti-vascular endothelial growth factor (VEGF) PCC.
Additionally, we provide an in-depth study of the stability
and stability limits of a recently described anti-protective
antigen (PA) PCC under physically demanding conditions
for in vitro detection. We illustrate that the PCC approach
can be utilized to mature ligands for speciﬁc in vivo and in
vitro applications for which mAbs may not be well suited.
2 | MATERIALS AND METHODS
2.1 | Materials
PA stock, recombinant from E. coli, NR-3780 was obtained
through the NIH Biodefense and Emerging Infections Research
Resources Repository, NIAID, NIH. The Anthrax PA meas-
ured by circular dichroism was obtained from List Labs (Lot:
17115A6B). Mouse anti-Bacillus anthracis PA monoclonal
antibody was purchased from US Biological Life Sciences, and
all surface plasmon resonance (SPR) chips were purchased
from GE Healthcare/Biacore Life Sciences. Recombinant
human VEGF (VEGF165) and VEGFR2 proteins and were
purchased from R&D Systems, and Bevacizumab (Avastin®;
BVZ) was purchased from Besse Medical. Bevacizumab Fab
(BVZ Fab) was generated by digestion with papain using the
PierceTM Fab Micro Preparation Kit. All chemicals for peptide
synthesis were acquired from AAPPTec. All additional chemi-
cals were purchased from Sigma-Aldrich and BDH Chemicals.
2.2 | Human plasma stability
Human plasma was pre-warmed at 378C for 5 min, followed
by addition of 5 mM AnchorV or Bi-LV with a ﬁnal DMSO
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concentration of 0.5% (v/v). The incubation was performed
in a 378C water bath for 0, 15, 30, 45, and 60 min. At each
time point, an aliquot of the incubation mixture was trans-
ferred to acetonitrile. Samples were then mixed and centri-
fuged. Supernatants were analyzed by HPLC-MS/MS
analysis (Agilent 1200 HPLC and a 5500 Qtrap Applied Bio-
systems Mass Spectrometer) using selected reaction monitor-
ing. The HPLC system consisted of a binary LC pump with
an autosampler, a C-18 column (Gemini C18, 2.1 3 50 mm,
5 micron; Phenomenex), and a gradient (Table S6, Support-
ing Information). Peak areas corresponding to the test com-
pound were recorded. The compound remaining (%) was
calculated by comparing the peak area at each time point to
time zero.
2.3 | Mouse liver microsome stability
The Bi-LV was pre-incubated with pooled mouse liver
microsomes (male CD-1, 0.3 mg/mL) in phosphate buﬀer
(pH 7.4) for 5 min in a 378C shaking water bath. The con-
centration of test compound was 1 mM with 0.01% DMSO,
0.25% acetonitrile, and 0.25% methanol. The reaction was
initiated by adding a NADPH-generating system (1.3 mM
NADP, 3.3 mM G6P, and 0.4 U/mL G6PDHase) and incu-
bated for 0, 15, 30, 45, and 60 min. The reaction was
stopped by transferring the incubation mixture to an equal
volume of acetonitrile/methanol (1/1, v/v). Samples were
then mixed and centrifuged. Supernatants were used for
HPLC-MS/MS analysis with selected reaction monitoring.
Peak areas corresponding to the test compound were
recorded and the compound remaining (%) was calculated by
comparing the peak area at each time point to time zero.
2.4 | In vivo pharmacokinetics (PK)
2.4.1 | Sample collection from mice (parallel sampling)
Experiments were performed as speciﬁed in Supporting
Information, Tables S2–S4. Brieﬂy, plasma concentrations
and pharmacokinetics of anti-VEGF PCC agents were stud-
ied in groups of 24 mice after IV or IP administration at a
single dose rate of 1 or 5 mg/kg body weight, respectively.
Animals were sedated under general inhalant anesthesia (3%
isoﬂurane) for blood collection by cardiac puncture. Each
mouse was subject to one blood draw. For IV groups, blood
was drawn from each of three animals at the following time
points: 3, 10, 30, 60, 120, 240, 360, 1,440 min. For IP
groups, blood was drawn from each of three animals at the
following time points: 10, 30, 60, 120, 240, 360, 480, 1,440
min. Blood aliquots (300–400 mL) were collected in tubes
coated with lithium heparin, mixed gently, then kept on ice
and centrifuged at 2,500g for 15 min at 48C, within 1 h of
collection. The plasma was then harvested and kept frozen at
2208C until further processing.
2.4.2 | Sample analysis
The LC-MS/MS system for analysis was comprised of an
Agilent 1200 high-performance liquid chromatography
(HPLC) and a 5500 Qtrap mass spectrometer (Applied Bio-
systems by Life Technologies, Carlsbad, CA). Concentra-
tions in mouse plasma were determined using a nonvalidated
LC-MS/MS assay with Angiotensin I as the internal standard
following solid phase extraction. Individual calibration and
QC standards were prepared from the respective intermediate
stock solutions by addition to naïve mouse plasma. The tar-
get working range of the calibration curve was 50–5,000 ng/
mL in plasma, and the target concentrations of the QC stand-
ards were 150–3,750 ng/mL in plasma.
Pharmacokinetic analysis was performed using WinNon-
lin Professional Edition (Pharsight Corporation, Version
5.2). Nominal dose levels and sample collection times were
used. Ratios and descriptive statistics were calculated using
WinNonlin or Microsoft Excel (Version 11.0). Values below
the lower limit of quantitation (BLQ) were treated as zero for
descriptive statistics and were excluded from pharmacoki-
netic analysis. Predose concentrations for IV dose groups
were excluded to allow for back extrapolation to concentra-
tion at time 0.
2.5 | MicroPET imaging of non-tumor-bearing mice
Female immunocompromised NU/J mice (6–7 weeks old)
were obtained from Jackson Laboratory. Mice were weighed
and subjected to general clinical observations. Experiments
were performed according to Institutional Animal Care and
Use Committee (IACUC) guidelines set forth by MPI
Research.
The 1,4,7,10-tetraazacyclododecane-N,N0,N00,N000-tetra-
acetic acid (DOTA)-labeled Tri-LV was radiolabeled by che-
lation with 64Cu. Radiolabeling was performed for 1 h with
47–84% radiochemical yields. Imaging was performed on
the non-tumor-bearing mice after injection of 64Cu-DOTA-
labeled Tri-LV (MALDI-MS (m/z): calcd. for
C224H331N61O66S3 (M
1) 5027.4; found (M1H) 5030.7.) in
a microPET (Focus 120, Siemens Medical Solutions), fol-
lowed by CT. Mice (n5 3) were administered 200 mCi (65
mg) of 64Cu-DOTA-Tri-LV via IV or IP injection. A
dynamic imaging scan was conducted from 0 to 2 h post-
dose, and static imaging scans were conducted for 15 or 30
min at 4 and 20 h postdose, respectively, for all animals. The
data reconstructed from PET and CT were visualized and
coregistered using VivoQuantTM software (inviCRO, LLC).
2.6 | MicroPET-CT imaging of mouse tumor model
VEGF-positive human HT-29 colon adenocarcinoma tumor
cells [5 3 106 cells prepared in 100 lL of serum-free culture
medium/Matrigel (1:1)] were inoculated on the left rear
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ﬂanks of female immunocompromised NU/J mice to result in
subcutaneous xenografts. Imaging was performed on the
xenografted mice after 20 h post injection of 64Cu-DOTA-
Tri-LV in a microPET, followed by CT. Mice were adminis-
tered 200 lCi (65 lg) of 64Cu-DOTA-Tri-LV via IP injec-
tion. For blocking experiments, animals received an IV bolus
injection of 100 lL unlabeled BVZ (1 mg) at 48 h (62 h)
before the IP administration of 64Cu-DOTA-Tri-LV, since
BVZ and the triligand would target the same human VEGF
epitope, leading to the decreased accumulation of 64Cu-
DOTA-Tri-LV in the tumor. BVZ was prepared fresh by
diluting stock in vehicle (0.9% NaCl for Injection, USP)
prior to dosing.
2.7 | HPLC and mass spectrometry
Five separate 100 mL aliquots of a 1 mg/mL sample of
Bi-LPA in PBS were heated at 258C, 708C, 808C, 908C, and
1008C for 60 min, respectively. After heating, the samples
were immediately put on ice. Three microliter of each sample
was injected into an Agilent 1200 series analytical HPLC
and through an Agilent Eclipse XBD-C18 column, with an
elution gradient of 20–60% acetonitrile in 0.1% triﬂuoroace-
tic acid in water over 35 min. The samples were monitored
at 280 nm.
The mass measurement of each heated sample was per-
formed on a Shimadzu Axima-CFR MALDI-TOF in linear
mode with a N2 laser. The laser power was set at 110–120
and the sample was mixed with a matrix of 10 mg/mL 2,5-
dihydroxybenzoic acid (DHB).
2.8 | Thermoﬂuor assay
Thermal aggregation studies were performed using the Pro-
teoStat Thermal Shift Stability Assay (Enzo Life Sciences). 1
and 15.5 mg/mL concentrations of Bi-LPA were studied in
5% DMSO in the assay buﬀer provided with the kit. Anti-
Bacillus anthracis PA mAb was diluted to a concentration of
0.2 mg/mL in assay buﬀer. The ﬂuorescence of each sample
was read using the LightCycler 480 system (Roche) at
498 nm excitation and 610 nm emission, while heating the
samples from 25 to 998C at 0.28C/min.
2.9 | Enzyme linked immunosorbent assay (ELISA)
Two 650 mL (25 mM) solutions of Bi-LPA were prepared in
PBS. One solution was heated for 1 h at 708C and allowed to
equilibrate to room temperature. Eleven serial dilutions from
25 to 0.012 mM were prepared with each Bi-LPA solution.
Assays were performed using the previously described
detailed protocol[19b] and run in triplicate.
2.10 | Surface plasmon resonance thermo activity assay
RU (30,000) of recombinant PA was amine-coupled to a
Biacore T200 series S sensor chip CM5. Bi-LPA was diluted
to 1 mg/mL in PBS, aliquoted in 100 mL volumes, and
heated to 908C for 15, 30, 45, and 60 min. After each time
point, samples were pulled and immediately put on ice. One
sample was left unheated. A calibration curve of unheated
sample was created by injecting 25, 50, 100, 150, 200, 250,
and 300 mM over the PA surface. One control sample was
run at 175 mM every 25 injection cycles to ensure the sensor
surface was not degraded over time. Heated samples for each
time point (0, 15, 30, 45, and 60 min) were diluted 1:1.5 in
PBS and plotted on the calibration curve using BiaEvaluation
software to determine active concentration. All samples were
evaluated in a Biacore T200 SPR instrument. Activity was
plotted relative to the control sample with standard deviation.
3 | RESULTS AND DISCUSSION
The PCC method was used to improve an anti-VEGF peptide
as a stable in vivo imaging probe and an anti-PA peptide as
an in vitro detection reagent suitable for demanding physical
environments. We ﬁrst characterized the in vitro properties
of the anti-VEGF peptide and then tracked the stepwise
improvements in aﬃnity, selectivity, and stability after each
in situ click screen. We then focused our eﬀorts on studying
the in vivo properties of the biligand and triligand. The syn-
thetic ﬂexibility of the PCC method permitted us to attach
site-speciﬁc labels to ligands for the in vitro assays, or radio-
labels, for the in vivo assays described below.
3.1 | Anti-VEGF PCCs: (In vitro) aﬃnity, selectivity, and
stability maturation
We developed an anti-VEGF PCC as a positron emission
tomography (PET) probe for in vivo imaging. We began by
maturing a phage display-derived, literature-based anti-
VEGF cyclic peptide ligand[22] into a biligand using an in
situ click screen (see Supporting Information for experimen-
tal details).[18c,19a] AnchorV (X-VEPNCDIHVMWEWEC-
FERL-Az4) was obtained by modifying the cyclic peptide
with a biotin-PEG3 label (5 X, Figure 1) and an azide-
containing amino acid (Az45 L-azidolysine). A disulﬁde
bridge was formed between the two cysteine thiols to cyclize
the underlined region of AnchorV. AnchorV exhibited an
EC505 1406 21 nM, which represents good binding to
VEGF, but an improved aﬃnity would be needed to be com-
petitive with either the anti-VEGF monoclonal antibody
BVZ (EC505 0.176 0.02 nM) or the monovalent BVZ Fab
(EC505 4.66 0.3 nM) (Figure 2A). Inhibition assays further
showed that AnchorV weakly binds to a common epitope
that is implicated in the binding of VEGF to its cognate
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receptor, VEGFR2 (KDR) (Figure 2B). AnchorV exhibited
insuﬃcient selectivity to capture VEGF from (diluted to
25%) serum samples in an immunoprecipitation experiment
(Figure 2C).
AnchorV was matured by in situ click screening
against VEGF165 and a one-bead–one-compound
(OBOC) D-peptide library terminated with the comple-
mentary alkyne. Scheme 1 illustrates the general strategy
for using the VEGF target to template the formation of
biligands by combining a library of synthetic peptides
with AnchorV. Several anti-VEGF biligand PCCs with
improved binding towards VEGF165 (Figures S3–S4,
Supporting Information) were identiﬁed by this approach.
Although there was no signiﬁcant diﬀerence in aﬃnity
between the biligands, Bi-Lv showed more signiﬁcant
capture of VEGF in immunoprecipitation studies from
25% human serum. Bi-LV (X-VEPNCDIHVMWEWEC-
FERL-Tz4-lfrew) exhibited a 4.5-fold improvement in
EC50 relative to AnchorV (Figure 2A), but did not com-
pete as eﬀectively as AnchorV for the VEGFR2 binding
site (Figure 2B). Bi-LV could be used to immunoprecipi-
tate VEGF from 25% human serum (Figure 2C) and is
therefore more selective than AnchorV.
The biological stabilities of AnchorV and Bi-LV in
human plasma were also compared. Bi-L showed an
improved stability, with> 80% of the peptide remaining after
incubation in human plasma for 60 min at 378C (Figure 2D).
Bi-LV also showed a high resistance to metabolic degrada-
tion by mouse liver microsomes (Figure 2E). This excellent
biological stability almost certainly results from the introduc-
tion of proteolysis resistant D-amino acids, and so, such
amino acids were used for further iterative improvements of
this PCC.[23,24]
The improved in vitro performance metrics of Bi-LV
prompted us to study this PCC in vivo (see next section) and
to further mature the PCC via in situ click screening into a
consensus triligand (Tri-LV, X-VEPNCDIHVMWEWEC-
FERL-Tz4-lfrew-Tz4-eeird) (Supporting Information, Fig-
ures S7–S9) and tetraligand (Tetra-LV, X-
VEPNCDIHVMWEWECFERL-Tz4-lfrew-Tz4-eeird-Tz4-
qfkyr) (Supporting Information, Figures S12 and S13).
Each in situ click screen iteration yielded improvements
in both binding aﬃnity and selectivity, with Tetra-LV
(EC505 6.16 0.2 nM) exhibiting performance compara-
ble to the BVZ Fab (Figures 2A–2C). Both Tri-LV and
Tetra-LV exhibited immunoprecipitation of VEGF from
25% human serum that was similarly comparable to that
of BVZ. The inhibition of VEGF binding to VEGFR2 was
also improved for both Tri-LV (IC505 2.66 0.5 nM) and
Tetra-LV (IC505 0.746 0.05 nM). Tetra-LV provides a
demonstration of what can be achieved using the iterative
in situ click approach. However, as a synthetic peptide, it
is a bit unwieldy for in vivo applications. Thus, we pushed
Bi-LV and Tri-LV forward for those studies.
3.2 | Anti-VEGF PCC: (In vivo) PK analysis and
targeting
The ability to chemically tailor the size and stability of PCCs
can be useful for in vivo applications such as PET molecular
imaging. We radiolabeled the anti-VEGF PCCs Bi-LV and
Tri-LV for studying, in vivo in mice, their pharmacokinetics
(PK) for diﬀerent routes of administration. We then showed
that radiolabeled Tri-LV ﬁnds its target in vivo by PET
imaging.
PK describes the time course of the level of an adminis-
tered compound in the body. Smaller molecules generally
exhibit rapid (<1 h) body clearance and improved tissue
penetration, while reagents >70 kDa often circulate for
much longer times.
The PK of Bi-LV and Tri-LV was performed following
intravenous (IV) and intraperitoneal (IP) dosing to mice.
Concentration-time proﬁles for each compound and route of
administration are shown in Figure 3A, and the calculated
PK parameters are summarized in the Supporting Informa-
tion (Table S5). The clearance of the PCCs was similar to
FIGURE 1 Maturation of an anti-VEGF PCC agent.
X5 detection label
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other peptides.[24] Following IV administration of Bi-LV, the
mean elimination half-life (T1/2) is 7 min, which represents a
rapid in vivo clearance of Bi-LV. Tri-LV, as an iterated PCC
with increased molecular size, allowed us to extend the in
vivo clearance to T1/25 36 min (by IV). This, and the other
PK values (Table S5), imply that Tri-LV provides more
favorable PK characteristics for in vivo PET imaging,[4]
where relatively short circulation times with rapid target vis-
ualization are desirable.
Tri-LV was prepared as an N-terminal DOTA conjugate
and then radiolabeled (see Methods) with 64Cu by chelation.
The in vivo biodistribution of radiolabeled Tri-LV was char-
acterized using PET imaging following either IV or IP injec-
tion into healthy mice. PET scans displayed in vivo kinetics
that are dependent on the route of administration. IV injec-
tion resulted in rapid renal clearance (Figure 3B). IP injection
resulted in slow clearance from the peritoneal cavity and kid-
ney retention at extended times (Figure 3C). In either case,
the majority of the PCC cleared to the kidneys and bladder
by 4 h postinjection. Because of the relatively short half-life
of Tri-LV, an IP route of administration was prioritized for
further PET imaging studies.
A mouse model of human HT-29 colorectal carcinoma
was used to study whether the radiolabeled Tri-LV is capa-
ble of binding to VEGF in a tumor in vivo. This model
expresses VEGF and is characterized by VEGF-dependent
radial tumor growth.[25] Mice bearing HT-29 xenograft
tumors in their rear ﬂanks were imaged by PET-CT with
radiolabeled Tri-LV-administered IP (Figure S14A, Support-
ing Information). To determine speciﬁcity for human VEGF,
unlabeled excess BVZ (1 mg) was preinjected prior to imag-
ing to block the target in vivo. Pretreatment with BVZ was
found to reduce tumor accumulation of radiolabeled Tri-LV
at 20 h and suggests binding to a shared VEGF epitope in
FIGURE 2 In vitro assays of anti-VEGF PCCs. (A) Relative aﬃnities of PCCs compared to Bevacizumab (BVZ) and Bevacizu-
mab Fab (BVZ Fab). (B) Inhibition of VEGF binding to VEGFR2 in the presence of PCCs and BVZ Fab. (C) Immunoprecipitation
of VEGF from PBS (P) and 25% human serum (S) for PCCs as compared to BVZ. (D) Stability ofAnchorV andBi-LV in human
plasma at 378C. (E) Stability ofBi-LV in mouse liver microsomes at 378C
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vivo (Figure S14B). In the tumor was observed a 32% block-
age (P5 0.004) of radiolabeled Tri-LV uptake by BVZ.
3.3 | Anti-VEGF PCC: Synthesis on solid-phase
Once identiﬁed, each PCC is synthesized on a larger scale on
acid-cleavable polystyrene resin. As a consequence of the in
situ click screen, a triazole (Tz) connects pairs of peptide
ligands via their terminal side chains of Az4 and D-propar-
gylglycine. A commercial peptide synthesizer employing
standard Fmoc/HBTU chemistry was used to couple amino
acids to the growing peptide chain and to incorporate the Tz.
We prepared a protected 1,4-Triazole linker (see Supporting
Information for synthetic details) as a dipeptide building
block to assist with synthesizing Tz-containing peptides. It
was compatible with peptide synthesis on a commercial pep-
tide synthesizer and enabled the synthesis of PCCs using a
single automated program.
Figure 4 illustrates the steps that were used in the synthe-
sis of Tri-Lv as an example. The tertiary ligand (eeird), 1,4-
Triazole linker, secondary ligand (lfrew), 1,4-Triazole linker,
and anchor (VEPNCDIHVMWEWECFERL) were coupled
to the resin in series. Following global side chain deprotec-
tion and resin cleavage, the disulﬁde bridge was formed. The
crude peptide was subsequently puriﬁed by HPLC on a C18
reversed-phase column.
3.4 | Anti-protective antigen (PA) PCC biligand: stability
studies
High thermal stability of a capture agent can enable the use
of that ligand in demanding physical environments removed
from refrigeration chains.[2] The binding characteristics of
antibodies and protein scaﬀolds to a speciﬁc antigen typi-
cally rely upon their secondary and/or tertiary structures in
solution. When these folded structures are exposed to heat,
the intramolecular forces and disulﬁde bonds that are
required to hold the reagent in its native state are altered,
resulting in an unfolded, inactive reagent that is not easily
refolded. The denaturing phenomenon can be observed in
SCHEME 1 In situ click screening of VEGF. A randomized pentapeptide library (X5 18 D-amino acids) is synthesized on
TentaGel resin. D-propargylglycine is ﬁxed at the N-terminus, and D-methionine is ﬁxed at the C-terminus (I). This library is incu-
bated with VEGF165 and Biotin-labeledAnchorV in a biligand screen (II). Target binding is detected by anti-VEGF165 antibody
followed by an alkaline phosphatase (AP)-conjugated secondary antibody. The hit beads are washed, stripped, and reprobed with
AP-conjugated streptavidin to detect products of the target-catalyzed in situ click chemistry (III-IV). Methionine-speciﬁc CNBr
cleavage and sequencing byMALDI-TOF/TOF yield the sequences of biligand candidates. The biligand candidates are synthesized
on a larger scale and assayed to assess in vitro performance (aﬃnity, selectivity, stability, etc.). Repeating the process once yields
triligands and twice results in tetraligands
COPPOCK ET AL. | 7 of 13
the CD spectrum of a commercially available anti-PA anti-
body heated to 908C (Figure S15, Supporting Information).
Short peptide reagents typically exhibit a weaker dependence
upon secondary or tertiary structure for binding, and can,
therefore, potentially display improved thermal stabilities in
solution. The anti-PA biligand (Bi-LPA) follows this trend by
exhibiting a random irregular structure in solution,[26] based
on circular dichroism measurements.[27] The random coil
structure of Bi-LPA is unaﬀected after multiple rounds of
heating up to 908C.
The unfolding of antibodies typically results in signiﬁ-
cant aggregation of the structures. Similar aggregation of
peptides in solution is not uncommon,[28] and in the case
of bio-detection, can greatly reduce the activity of the rea-
gent. The onset of peptide aggregation is largely dependent
upon amino acid sequence, with the content of hydropho-
bic residues typically leading to a higher probability of
aggregation.[29] Bi-LPA aggregation was studied between
258C and 998C with a Thermal Shift Assay Kit (Proteo-
Stat). The assay uses a ﬂuorescent dye that detects protein
aggregation resulting from thermal denaturation. At a con-
centration of 1 mg/mL, Bi-LPA does not exhibit signs of
aggregation (Figure 5A), whereas at a signiﬁcantly higher
concentration of 15.5 mg/mL there is only evidence of
rapid biligand solvation occurring around 478C, as seen in
Figure 5B inset. As a comparison, the commercially avail-
able anti-PA monoclonal antibody denatures and aggre-
gates at 668C (Figure 5C).
In terms of chemical stability, Bi-LPA does not exhibit
any fragmentation or signiﬁcant structural change after heat-
ing for 1 h up to 1008C in solution, as determined by mass
spectrometry (ms) and HPLC analysis (Figure 6A). The
mass spectra reveal comparable patterning dominated by
the M1 peak of the biligand, while the HPLC traces elute
the sample at analogous times and with similar peak areas,
along with no indication of an increase or introduction of
decomposition products. In fact, Bi-LPA must be heated up
to 1708C in the solid state to observe the onset of a melting
endotherm (Figure S16, Supporting Information), which is
comparable to other peptide melting points.[30] Not all prod-
ucts of chemical degradation will be detected via HPLC or
ms analysis. For example, a deamidation reaction could rear-
range asparagine to the inactive isoaspartate form,[31] result-
ing in at most a 1 g/mol diﬀerence in molecular weight, with
little to no change in the polarity of the speciﬁc amino acid
side group. Thus, we further explored thermal stability via
FIGURE 3 In vivo assays of anti-VEGF PCCs. (A) Pharmacokinetics proﬁles ofBi-LV andTri-LV following a single IV or IP
dose in mice. (B) In vivomicroPET-CT images (coronal slices) of nude mice demonstrating renal clearance of 64Cu-DOTA-
labeledTri-LV administered IV. (C) In vivomicroPET-CT images of 64Cu-DOTA-labeledTri-LV for the samemice administered
IP
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the impact of heating on immunoassays that employ the
PCC.
3.4.1 | Thermal activity
We investigated the inﬂuence of temperature on Bi-LPA in
buﬀer solution through activity studies. A thermal challenge
precedence was set during an antibody engineering study as
part of the Defense Advanced Research Projects Agency
(DARPA) Antibody Technology Program[32] through accel-
erated lifetime testing. According to the DARPA standard, a
highly eﬀective reagent retains >85% activity after heating
at 708C for 1 h.[5] As an initial test of the thermal eﬀect on
the activity of Bi-LPA, we performed an ELISA before and
after heating at 708C for 1 h. As shown in Figure 6B, the KD
for unheated Bi-LPA is 2166 7 nM, whereas the KD after an
hour is 283 nM6 27 nM, suggesting insigniﬁcant reduction
in KD after the reagent is heated, surpassing the 708C for 1 h
precedence. The high eﬃcacy of the reagent suggests that it
is extremely competitive with antibody replacements
reported in the literature that also demonstrate high thermal
stability.[6]
We further investigated Bi-LPA following heating under
the more extreme condition of 908C. By creating a linear cal-
ibration curve (Supporting Information, Figure S17) using
relative Rmax from the analyte injections of unheated bili-
gand, we were able to plot responses of our heated samples
and extrapolate initial sample concentrations based on the
dilution factors used. The calculated concentrations were
used to calculate the percent activity of each heated sam-
ple.[6] The reagent retained 81% of its activity compared to
unheated Bi-LPA after 1 h of heating at 908C, as shown in
Figure 6C. The determined activity is 20% higher than the
best known modiﬁed antibody at this high temperature and
time scale,[5] and to the best of our knowledge is the most
thermally stable and functional biorecognition reagent
known to date. The ability of Bi-LPA and other reagents dis-
covered through the PCC technology to retain activity at
such high temperatures makes it an extremely eﬀective rea-
gent for detection of biothreats outside of a laboratory
FIGURE 4 Solid-phase synthesis ofTri-LV. Amino acids are shown in one-letter code, with L-amino acids in uppercase and
D-amino acids in lowercase. Reagents and conditions: (A) standard Fmoc/HBTU chemistry; (B) 1,4-Tz Linker (4 eq.), HATU (3.8
eq.), DIEA (10 eq.); (C) standard Fmoc/HBTU chemistry; (D) 1,4-Tz Linker (4 eq.), HATU (3.8 eq.), DIEA (10 eq.); (E) standard
Fmoc/HBTU chemistry; (F) TFA/H2O/TES (95/2.5/2.5) for 4 h, followed by ether precipitation; (G) intramolecular disulﬁde
cyclization for 4–16 h in 0.05M ammonium acetate1 10% (v/v) DMSO at pH 7–8
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FIGURE 5 Thermal Shift Assay of (A) 1 mg/mLBi-LPA, (B) 15.5 mg/mLBi-LPA, and (C) anti-PAmonoclonal antibody. The
insets of (B) and (C) correspond to the ﬁrst derivative of the collected data
FIGURE 6 (A)Mass spectrum and HPLC trace ofBi-LPA after 1 h heating at each respective temperature: 258C, 708C, 808C,
908C, and 1008C. (B) ELISAmeasurements of theBi-LPA before heating (black; KD5 216 nM6 7 nM) and after 1 h at 708C (red;
KD5 283 nM6 27 nM). (C) SPR activity assay ofBi-LPA against PA at 908C for 1 h
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environment that can easily be incorporated into a wide
range of detection devices.
3.4.2 | Isoaspartate content
The most signiﬁcant contributor to a loss of activity of a
non-aggregating peptide with no secondary structure and no
fragmentation upon heating is most likely caused by non-
enzymatic degradation. Commonly when a peptide is heated,
the rate of intramolecular hydrolysis or deamidation reactions
between amino acids greatly increases, yielding a mixture of
isoaspartic acid (typically 70–85%) and aspartic acid.[33] The
rate of these reactions is sequence-dependent and is most fre-
quent when Asparagine, Aspartic acid, or Glutamine are
present next to a Glycine in an oligopeptide sequence,
though the Glutamine rearrangement occurs at a much
slower rate.[34] Based on the Bi-LPA sequence (elfhn-tria-
zole-YGLHPWWKNAPIGQR), the Asp-Ala combination
has the highest potential of rearranging to isoaspartate, which
could diminish the activity of the PCC after heating.
The quantiﬁcation of isoaspartate was performed on a
solution of Bi-LPA heated at 908C for 1 h using an ISO-
QUANT Isoaspartate Detection Kit (Promega). Isoaspartate
was present in the sample after 15 min of heating and
increased in a linear fashion, as aliquots were tested every 15
min (Supporting Information, Figure S18). When compared
to the total amount of biligand in the solution, there is only a
small fraction of a percent of isoaspartate created per pico-
mol of biligand after 1 h at 908C, described in Table S1.
While the amount of isoaspartate generated is low, it could
help explain the loss of activity as determined by SPR at
908C.
Understanding mechanisms for activity loss oﬀers
insight into the further design of the PCC peptide screening
libraries, using the bottom-up approach of this technology.
One potential approach in reducing isoaspartate production
is to substitute and screen diﬀerent hydrophobic amino
acid side chains in the Alanine position adjacent to Aspara-
gine, providing an increase in steric hindrance, and reduc-
ing the opportunity for intramolecular cyclization. The
Asparagine or Glutamine residues, themselves, could also
potentially be substituted with other polar amino acid side-
chains, preventing deamidation.
4 | CONCLUSIONS
The capability of tailoring desired characteristics of capture
agents including aﬃnity/selectivity, size, chemical/biological
stability, and temperature stability through the PCC screen-
ing process has the potential to provide highly eﬀective syn-
thetic antibody replacements for a range of in vitro and in
vivo applications. The anti-VEGF PCCs exhibit varying
aﬃnities and selectivities, dependent upon the degree of mat-
uration, with a high degree of biological stability arising
from the incorporation of D-amino acids into the matured
reagents. The in vitro performance of Tetra-LV was closest
to the Fab fragment of BVZ, the anti-VEGF monoclonal
antibody. Tri-LV exhibited in vivo binding to VEGF and at
an epitope shared with BVZ. We are exploring additional
assays for guiding PCC development for in vivo perform-
ance, including ADME preclinical studies [absorption, distri-
bution, metabolism, and excretion], imaging with PEGylated
compositions, and drugging studies in a rodent tumor xeno-
graft model.
The heating studies with an anti-PA PCC show that the
thermal stability of PCC agents is limited mainly by intramo-
lecular reactions, leading to a slight loss in activity under
prolonged exposure at extreme temperatures (908C). The rate
of isoaspartate production and other intramolecular interac-
tions are mostly sequence-dependent. This rate could likely
be reduced by altering the amino acid composition of the ini-
tial screening library by completely removing the amino
acids that exhibit deamidation and hydrolysis such as aspara-
gine, aspartic acid, and glutamine. Additionally, substitution
of these amino acids with unnatural analogs such as nitro or
ﬂuorinated side groups could also result in similar, if not bet-
ter, performing properties. We are currently looking towards
the use of cyclic peptides to provide even greater stability,
since the rate of such intramolecular reactions is greatly
reduced,[35] and the cyclic peptides tend to yield higher aﬃn-
ities and selectivities from even fewer screening steps.[36]
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